BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34022524)

  • 1. A multivariable prediction model of a major treatment response for focal-onset seizures: A post-hoc analysis of Phase III trials of perampanel.
    Krauss GL; Ben-Menachem E; Wechsler RT; Patten A; Williams B; Laurenza A; Malhotra M
    Epilepsy Res; 2021 Aug; 174():106649. PubMed ID: 34022524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
    Steinhoff BJ; Patten A; Williams B; Malhotra M
    Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained seizure freedom with adjunctive perampanel in patients with convulsive seizures: Post hoc analysis of open-label extension studies 307 and 332.
    Resnick T; Patten A; Ngo LY; Malhotra M
    Epilepsy Behav; 2022 Mar; 128():108528. PubMed ID: 35078116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India.
    Mehndiratta MM; Gulhane M; Jabeen SA; Patten A; Dash A; Malhotra M
    Epilepsia Open; 2021 Mar; 6(1):90-101. PubMed ID: 33681652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
    Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
    CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL; Perucca E; Kwan P; Ben-Menachem E; Wang XF; Shih JJ; Patten A; Yang H; Williams B; Laurenza A
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy.
    Inoue Y; Kaneko S; Hsieh PF; Meshram C; Lee SA; Aziz ZA; Nabangchang C; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():60-67. PubMed ID: 30869167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
    Nishida T; Lee SK; Wu T; Tiamkao S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE; Ferry J; Majid O; Hussein Z
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of adjunctive perampanel in patients from the Asia-Pacific region with refractory focal-onset seizures in Study 335 open-label extension.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Malhotra M; Patten A; Kaneko S
    Epilepsia Open; 2024 Apr; 9(2):501-512. PubMed ID: 37867420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy.
    Brandt C; Wechsler RT; O'Brien TJ; Patten A; Malhotra M; Ngo LY; Steinhoff BJ
    Seizure; 2020 Aug; 80():115-123. PubMed ID: 32563171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.
    Rektor I; Krauss GL; Inoue Y; Kaneko S; Williams B; Patten A; Malhotra M; Laurenza A; Wechsler RT
    Epilepsia; 2020 Jul; 61(7):1491-1502. PubMed ID: 32645213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
    Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
    Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
    Tsai JJ; Ikeda A; Hong SB; Likasitwattanakul S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
    Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
    Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of adjunct perampanel based on number of antiepileptic drugs at baseline and baseline predictors of efficacy: A phase III post-hoc analysis.
    Glauser T; Laurenza A; Yang H; Williams B; Ma T; Fain R
    Epilepsy Res; 2016 Jan; 119():34-40. PubMed ID: 26656783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the long-term efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of open-label extension studies.
    Piña-Garza JE; Villanueva V; Rosenfeld W; Yoshinaga H; Patten A; Malhotra M
    Epilepsy Behav; 2022 Oct; 135():108901. PubMed ID: 36122531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
    French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
    Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.